Interleukin-7 is a growth factor for Sézary lymphoma cells
- PMID: 1381718
- PMCID: PMC329964
- DOI: 10.1172/JCI115920
Interleukin-7 is a growth factor for Sézary lymphoma cells
Abstract
Sézary syndrome is a cutaneous T cell lymphoma characterized by infiltration of the skin by CD4+ cells. These cells generally respond poorly to mitogens and T cell activators. We have studied the action of IL1 to IL4, IL6, and IL7 on the proliferation of Sézary cells from 12 patients. With the exception of IL2 and IL7, the cytokines studied had no proliferative effect on these cells. Whereas IL2 had only a low proliferative capacity (two- to threefold increase) on peripheral blood mononuclear cells, recombinant IL7 constantly induced a very significant (3-40-fold increase) proliferative response, and was used successfully to generate cell lines in three out of eight cases. Growth of Sézary cell lines was shown to be strictly dependent on IL7, and after 2-5 wk of culture presented a switch to a homogeneous phenotype CD3+4+8-7- (except for one line that remained CD7+), with a typical morphology of Sézary cells. Their tumoral origin was demonstrated by the expression of the same T cell receptor-beta gene rearrangement as the patients' T cells. Importantly, cultured normal epidermal keratinocyte supernatants could support the growth of our Sézary lines. Furthermore, the proliferative activity contained in these supernatants was completely blocked by a monoclonal anti-IL7 antibody. These results suggest that IL7 may, therefore, represent an important cytokine in the physiopathology of cutaneous T cell lymphoma.
Similar articles
-
Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.J Clin Oncol. 1994 Feb;12(2):326-35. doi: 10.1200/JCO.1994.12.2.326. J Clin Oncol. 1994. PMID: 8113839
-
CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.J Am Acad Dermatol. 2001 Mar;44(3):456-61. doi: 10.1067/mjd.2001.110900. J Am Acad Dermatol. 2001. PMID: 11209115
-
Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.J Clin Invest. 1981 Feb;67(2):523-30. doi: 10.1172/JCI110062. J Clin Invest. 1981. PMID: 6970206 Free PMC article.
-
Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.J Am Acad Dermatol. 2012 Mar;66(3):503-8. doi: 10.1016/j.jaad.2011.06.014. Epub 2011 Oct 17. J Am Acad Dermatol. 2012. PMID: 22005074 Review.
-
[Epidermotropic T cell lymphomas as models for tumor progression].Med Sci (Paris). 2006 Feb;22(2):192-6. doi: 10.1051/medsci/2006222192. Med Sci (Paris). 2006. PMID: 16457762 Review. French.
Cited by
-
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.Front Immunol. 2017 Aug 30;8:1010. doi: 10.3389/fimmu.2017.01010. eCollection 2017. Front Immunol. 2017. PMID: 28912774 Free PMC article. Review.
-
Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma.Blood. 2006 Mar 15;107(6):2440-5. doi: 10.1182/blood-2005-03-1139. Epub 2005 Dec 1. Blood. 2006. PMID: 16322477 Free PMC article.
-
Targeting CD47 in Sézary syndrome with SIRPαFc.Blood Adv. 2019 Apr 9;3(7):1145-1153. doi: 10.1182/bloodadvances.2018030577. Blood Adv. 2019. PMID: 30962222 Free PMC article. Clinical Trial.
-
Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease.Am J Pathol. 1995 Jan;146(1):33-9. Am J Pathol. 1995. PMID: 7856736 Free PMC article.
-
A mouse model for the Sézary syndrome.J Exp Clin Cancer Res. 2010 Feb 11;29(1):11. doi: 10.1186/1756-9966-29-11. J Exp Clin Cancer Res. 2010. PMID: 20149229 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials